Insulin Attenuates Beta-Amyloid-Associated Insulin/Akt/EAAT Signaling Perturbations in Human Astrocytes

Cellular and Molecular Neurobiology

Volumn 36, Issue 6, 2016, Pages 851-864

  Han, Xiaojuan ^a   Yang, Liling ^a   Du, Heng ^b   Sun, Qinjian ^a   Wang, Xiang ^a   Cong, Lin ^a   Liu, Xiaohui ^a   Yin, Ling ^a   Li, Shan ^a   Du, Yifeng ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Alzheimer s disease; A 1 42 oligomers; Excitatory amino acid transporter; Human astrocytes; Insulin signaling

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; EXCITATORY AMINO ACID TRANSPORTER; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; GLIAL FIBRILLARY ACIDIC PROTEIN; INSULIN; INSULIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OLIGOMER; PHOSPHO INSULIN RECEPTOR; PHOSPHO MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHO PROTEIN KINASE B; PROTEIN KINASE B; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); GLUTAMATE TRANSPORTER; GLUTAMIC ACID; PEPTIDE FRAGMENT; SLC1A2 PROTEIN, HUMAN; SLC1A3 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN FUNCTION; BRAIN REGION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INSULIN TREATMENT; NERVE CELL PLASTICITY; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECTS; METABOLISM; NERVE CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASTROCYTES; CELLS, CULTURED; EXCITATORY AMINO ACID TRANSPORTER 1; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMIC ACID; HUMANS; INSULIN; NEURONS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84941342005     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-015-0268-5     Document Type: Article

References (54)

1. Avila-Munoz E, Arias C (2014) When astrocytes become harmful: functional and inflammatory responses that contribute to Alzheimer’s disease. Ageing Res Rev 18:29–40. doi:10.1016/j.arr.2014.07.004
2. Birch AM (2014) The contribution of astrocytes to Alzheimer’s disease. Biochem Soc Trans 42(5):1316–1320. doi:10.1042/bst20140171
3. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Investig 122(4):1339–1353. doi:10.1172/jci57256
4. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 285(17):13107–13120. doi:10.1074/jbc.M110.100420
5. Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, Nordberg A (2012) Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 53(1):37–46. doi:10.2967/jnumed.110.087031
6. Cassano T, Serviddio G, Gaetani S, Romano A, Dipasquale P, Cianci S, Bellanti F, Laconca L, Romano AD, Padalino I, LaFerla FM, Nicoletti F, Cuomo V, Vendemiale G (2012) Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging 33(6):1121.e1. doi:10.1016/j.neurobiolaging.2011.09.021
7. Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, Car J, Middleton L, Russ TC, Deary IJ, Campbell H, Rudan I (2013) Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet 381(9882):2016–2023. doi:10.1016/s0140-6736(13)60221-4
8. Chen Y, Deng Y, Zhang B, Gong CX (2014) Deregulation of brain insulin signaling in Alzheimer’s disease. Neurosci Bull 30(2):282–294. doi:10.1007/s12264-013-1408-x
9. Cole GM, Frautschy SA (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease. Exp Gerontol 42(1–2):10–21. doi:10.1016/j.exger.2006.08.009
10. Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, Oliveira CR, Moreira PI (2012) Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer’s disease and diabetes interrelation. Brain Res 1441:64–78. doi:10.1016/j.brainres.2011.12.063
11. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1):29–38. doi:10.1001/archneurol.2011.233
12. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65(1):1–105
13. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 106(6):1971–1976. doi:10.1073/pnas.0809158106
14. de la Monte SM (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 9(1):35–66
15. de la Monte SM (2014) Type 3 diabetes is sporadic Alzheimers disease: mini-review. European Neuropsychopharmacol 24(12):1954–1960. doi:10.1016/j.euroneuro.2014.06.008
16. Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, Rego AC (2012) Amyloid beta peptide 1–42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 51(2):95–106. doi:10.1016/j.ceca.2011.11.008
17. Franke TF (2008) PI3K/Akt: getting it right matters. Oncogene 27(50):6473–6488. doi:10.1038/onc.2008.313
18. Giaume C, Kirchhoff F, Matute C, Reichenbach A, Verkhratsky A (2007) Glia: the fulcrum of brain diseases. Cell Death Differ 14(7):1324–1335. doi:10.1038/sj.cdd.4402144
19. Gibbs ME, Hutchinson D, Hertz L (2008) Astrocytic involvement in learning and memory consolidation. Neurosci Biobehav Rev 32(5):927–944. doi:10.1016/j.neubiorev.2008.02.001
20. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O’Connor R, O’Neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem 93(1):105–117. doi:10.1111/j.1471-4159.2004.02949.x
21. Gupta A, Dey CS (2012) PTEN, a widely known negative regulator of insulin/PI3 K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell 23(19):3882–3898. doi:10.1091/mbc.E12-05-0337
22. Han X, Ma Y, Liu X, Wang L, Qi S, Zhang Q, Du Y (2012) Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer’s disease rat model. J Neural Transm 119(11):1407–1416. doi:10.1007/s00702-012-0803-1
23. Henneberger C, Papouin T, Oliet SH, Rusakov DA (2010) Long-term potentiation depends on release of d-serine from astrocytes. Nature 463(7278):232–236. doi:10.1038/nature08673
24. Hers I, Vincent EE, Tavare JM (2011) Akt signalling in health and disease. Cell Signal 23(10):1515–1527. doi:10.1016/j.cellsig.2011.05.004
25. Hulmi JJ, Silvennoinen M, Lehti M, Kivela R, Kainulainen H (2012) Altered REDD1, myostatin, and Akt/mTOR/FoxO/MAPK signaling in streptozotocin-induced diabetic muscle atrophy. Am J Physiol Endocrinol Metab 302(3):E307–315. doi:10.1152/ajpendo.00398.2011
26. Ito S, Menard M, Atkinson T, Gaudet C, Brown L, Whitfield J, Chakravarthy B (2012) Involvement of insulin-like growth factor 1 receptor signaling in the amyloid-beta peptide oligomers-induced p75 neurotrophin receptor protein expression in mouse hippocampus. J Alzheimer’s Dis 31(3):493–506. doi:10.3233/jad-2012-120046
27. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J Alzheimer’s Dis 11(1):97–116
28. Ji YF, Xu SM, Zhu J, Wang XX, Shen Y (2011) Insulin increases glutamate transporter GLT1 in cultured astrocytes. Biochem Biophys Res Commun 405(4):691–696. doi:10.1016/j.bbrc.2011.01.105
29. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, Masliah E (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer’s disease and correction by insulin. J Neurosci Res 86(15):3265–3274. doi:10.1002/jnr.21787
30. Kulijewicz-Nawrot M, Sykova E, Chvatal A, Verkhratsky A, Rodriguez JJ (2013) Astrocytes and glutamate homoeostasis in Alzheimer’s disease: a decrease in glutamine synthetase, but not in glutamate transporter-1, in the prefrontal cortex. ASN Neuro 5(4):273–282. doi:10.1042/an20130017
31. Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, Pradier L, Hugon J (2005) mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer’s disease. J Neurochem 94(1):215–225. doi:10.1111/j.1471-4159.2005.03187.x
32. Lafay-Chebassier C, Perault-Pochat MC, Page G, Rioux Bilan A, Damjanac M, Pain S, Houeto JL, Gil R, Hugon J (2006) The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide. J Neurosci Res 84(6):1323–1334. doi:10.1002/jnr.21039
33. Laplante M, Sabatini DM (2009) mTOR signaling at a glance. J Cell Sci 122(Pt 20):3589–3594. doi:10.1242/jcs.051011
34. Laron Z (2009) Insulin and the brain. Arch Physiol Biochem 115(2):112–116. doi:10.1080/13813450902949012
35. Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW (2009) The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol Biol Cell 20(5):1533–1544. doi:10.1091/mbc.E08-07-0777
36. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol 225(1):54–62. doi:10.1002/path.2912
37. Lopez-Colome AM, Martinez-Lozada Z, Guillem AM, Lopez E, Ortega A (2012) Glutamate transporter-dependent mTOR phosphorylation in Muller glia cells. ASN Neuro. doi:10.1042/an20120022
38. Machado-Neto JA, Favaro P, Lazarini M, Costa FF, Saad STO, Traina F (2011) Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. Biochim Biophys Acta 8:1404–1411. doi:10.1016/j.bbamcr.2011.04.002
39. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ (2010) Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia 58(7):831–838. doi:10.1002/glia.20967
40. On C (2013a) PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer’s disease. Exp Gerontol. doi:10.1016/j.exger.2013.02.025
41. On C (2013b) PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer’s disease. Exp Gerontol 48(7):647–653. doi:10.1016/j.exger.2013.02.025
42. Pearson-Leary J, McNay EC (2012) Intrahippocampal administration of amyloid-beta(1–42) oligomers acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism. J Alzheimer’s Dis 30(2):413–422. doi:10.3233/jad-2012-112192
43. Peters O, Schipke CG, Philipps A, Haas B, Pannasch U, Wang LP, Benedetti B, Kingston AE, Kettenmann H (2009) Astrocyte function is modified by Alzheimer’s disease-like pathology in aged mice. J Alzheimer’s Dis 18(1):177–189. doi:10.3233/jad-2009-1140
44. Ryan DA, Narrow WC, Federoff HJ, Bowers WJ (2010) An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. J Neurosci Methods 190(2):171–179. doi:10.1016/j.jneumeth.2010.05.001
45. Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, Bowman AB, Aschner M (2011) Role of astrocytes in brain function and disease. Toxicol Pathol 39(1):115–123. doi:10.1177/0192623310385254
46. Sukhorukova EG, Alekseeva OS, Kirik OV, Grudinina NA, Korzhevskii DE (2012) Comparative aspects of structural organization of astrocytes of the first layer of the human and rat cerebral cortex. Zh Evol Biokhim Fiziol 48(3):280–286
47. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Investig 122(4):1316–1338. doi:10.1172/jci59903
48. Tam JH, Pasternak SH (2012) Amyloid and Alzheimer’s disease: inside and out. Can J Neurol Sci 39(3):286–298
49. Wang Y, Wang K, Zhao J, Liu X, Bu J, Yan X, Huang R (2013) Multifunctional mesoporous silica-coated graphene nanosheet used for chemo-photothermal synergistic targeted therapy of glioma. J Am Chem Soc 135(12):4799–4804. doi:10.1021/ja312221g
50. Wharton SB, O’Callaghan JP, Savva GM, Nicoll JA, Matthews F, Simpson JE, Forster G, Shaw PJ, Brayne C, Ince PG (2009) Population variation in glial fibrillary acidic protein levels in brain ageing: relationship to Alzheimer-type pathology and dementia. Dement Geriatr Cogn Disord 27(5):465–473. doi:10.1159/000217729
51. Wu X, Kihara T, Akaike A, Niidome T, Sugimoto H (2010) PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. Biochem Biophys Res Commun 393(3):514–518. doi:10.1016/j.bbrc.2010.02.038
52. Yang Y, Ma D, Wang Y, Jiang T, Hu S, Zhang M, Yu X, Gong CX (2013) Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J Alzheimer’s Dis 33(2):329–338. doi:10.3233/jad-2012-121294
53. Zhang Q, Guo S, Zhang X, Tang S, Wang L, Han X, Shao W, Cong L, Du Y (2015) Amyloid beta oligomer-induced ERK1/2-dependent serine 636/639 phosphorylation of insulin receptor substrate-1 impairs insulin signaling and glycogen storage in human astrocytes. Gene 561(1):76–81. doi:10.1016/j.gene.2015.02.011
54. Zhou L, Chan KH, Chu LW, Kwan JS, Song YQ, Chen LH, Ho PW, Cheng OY, Ho JW, Lam KS (2012) Plasma amyloid-beta oligomers level is a biomarker for Alzheimer’s disease diagnosis. Biochem Biophys Res Commun 423(4):697–702. doi:10.1016/j.bbrc.2012.06.017